Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

PALOMA-3: Subcutaneous Amivantamab + Lazertinib for EGFR+ NSCLC

Video Series

PALOMA-3: Managing AEs

Videos

Joshua K. Sabari, MD, and Martin Dietrich, MD, PhD, examine both the evolution of first-line EGFR TKIs as standard treatment for EGFR-mutated metastatic non-small cell lung cancer and the ongoing clinical challenges in managing resistance, toxicities, and treatment sequencing in this space.

A panelist discusses how targeted therapies such as EGFR tyrosine kinase inhibitors have become the standard first-line treatment for patients with EGFR-mutated metastatic non–small cell lung cancer, offering improved outcomes compared with traditional chemotherapy.

EGFR mNSCLC Front-Line: Treatment Options

A panelist discusses how managing resistance mechanisms and toxicity profiles and identifying optimal sequencing strategies remain key challenges in treating EGFR-mutated metastatic non–small cell lung cancer despite advances in targeted therapies.

EGFR mNSCLC: Challenges with Treatments in this Space

Panelists discuss how managing adverse events and selecting optimal treatment strategies remain key challenges in front-line EGFR-mutated, non–small cell lung cancer (mNSCLC) therapy, particularly when weighing the efficacy and toxicity profiles of available targeted therapies.

EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs

Panelists discuss how PALOMA-3, a phase 3 randomized clinical trial, was designed to evaluate palbociclib plus fulvestrant vs placebo plus fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy.

PALOMA-3: Study Design and Baseline Characteristics

Panelists discuss how PALOMA-3’s pharmacokinetic and secondary end point analyses demonstrated the clinical benefit of palbociclib through multiple measures, including progression-free survival, objective response rate, and drug concentration levels that inform optimal dosing strategies.

PALOMA-3: Key End Points: Pharmacokinetic and Secondary

Panelists discuss how the safety profile of palbociclib plus fulvestrant in PALOMA-3 was characterized by manageable adverse events, with neutropenia being the most common but rarely leading to treatment discontinuation.

PALOMA-3: Key Safety Data

Panelists discuss how adverse events (AEs) associated with palbociclib plus fulvestrant can be effectively managed through dose modifications, supportive care measures, and careful monitoring of blood counts, enabling patients to maintain treatment continuity.

Panelists discuss how PALOMA-3’s findings have significantly impacted clinical practice by establishing palbociclib plus fulvestrant as a standard treatment option for patients with hormone receptor–positive, HER2-negative advanced breast cancer who have progressed on prior endocrine therapy.

PALOMA-3: Clinical Implications 

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

PALOMA-3: Managing AEs

EP: 1.EGFR mNSCLC Front-Line: Treatment Options

EP: 2.EGFR mNSCLC: Challenges with Treatments in this Space

EP: 3.EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs

EP: 4.PALOMA-3: Study Design and Baseline Characteristics

EP: 5.PALOMA-3: Key End Points: Pharmacokinetic and Secondary

EP: 6.PALOMA-3: Key Safety Data

EP: 7.PALOMA-3: Managing AEs

EP: 8.PALOMA-3: Clinical Implications